Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

As Pharma Falters, Shire Specialist Model Hits Sweet Spot

This article was originally published in The Pink Sheet Daily

Executive Summary

With product sales growth that most big pharmas can only dream of, Shire's specialist model is working.
Advertisement

Related Content

On A Revenue Roll, Shire Takes Specialist Tactics To “Primary Care” Markets
Shire And Atlas Venture To Work Together To Incubate Rare Disease Research Projects
Aiming For Better, Cheaper ERT Drugs, Oxyrane Raises $26.5 Mil.
Pharma Industry Pushes A Broadened Meaning For “Orphan”
Pharma Industry Pushes A Broadened Meaning For “Orphan”
Sanofi Says Genzyme Integration Is On Track, But Fabrazyme Production Won't Meet Goals
Sanofi Says Genzyme Integration Is On Track, But Fabrazyme Production Won't Meet Goals
Shire CEO Angus Russell On The Value Proposition For Drugs
Sanofi/Genzyme: Emblematic of What Big Pharma's Buying Now
Sanofi/Genzyme: Emblematic of What Big Pharma's Buying Now

Topics

Advertisement
UsernamePublicRestriction

Register

PS072665

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel